SHR4640 + placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gout; Hyperuricemia
Conditions
Gout; Hyperuricemia
Trial Timeline
Jul 1, 2016 → Mar 1, 2017
NCT ID
NCT02890966About SHR4640 + placebo
SHR4640 + placebo is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Gout; Hyperuricemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02890966. Target conditions include Gout; Hyperuricemia.
What happened to similar drugs?
7 of 20 similar drugs in Gout; Hyperuricemia were approved
Approved (7) Terminated (3) Active (11)
🔄SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02890966 | Phase 1 | Completed |
| NCT02815839 | Phase 1 | Completed |
Competing Products
20 competing products in Gout; Hyperuricemia